

RECEIVED

NOV 28 2001

TECH CENTER 1600/2900

SEQUENCE LISTING

<110> Cooper, Denise R  
Patel, Niketa A

<120> Introduction of a Glucose-Regulated Instability Element  
Via Alternative Exon Inclusion of PKCBII mRNA in  
Vascular Smooth Muscle Cells

<130> 114205-1200 Corrected

<140> 09/435,471

<141> 1999-11-08

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<220>

<223> Xaa at amino acid residues 2-6 is any amino acid  
residue.

<400> 1

Cys Xaa Xaa Xaa Xaa Xaa Arg  
1 5

<210> 2

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<223> Xaa at amino acid residue 1 is Ile or Val; Xaa at  
amino acid residue 10 is Ser or Thr; Xaa at amino  
acid residues 4 and 7 is any amino acid residue.

<400> 2

Xaa His Cys Xaa Ala Gly Xaa Gly Arg Xaa Gly  
1 5 10

<210> 3

<211> 9  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Xaa at residue positions 3-4, and 6-7 is any amino acid residue; Xaa at amino acid residue 9 is Ser or Thr.

<400> 3  
His Cys Xaa Xaa Gly Xaa Xaa Arg Xaa  
1 5

<210> 4  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

<400> 4  
cgtatatgcg gccgcgttgt gggcctgaag ggg

33

C1

<210> 5  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

<400> 5  
gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 6  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

<400> 6  
gcattcthtc cagtgaggag aa

22

<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

<400> 7  
aaccagcacg ttgccagga g

21

<210> 8  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

C1

<400> 8  
cgtatatgcg gccgcgttgt gggcctgaag ggg

33

<210> 9  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:  
oligonucleotide primer

<400> 9  
gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 10  
<211> 351  
<212> DNA  
<213> Human PKC Beta II

<400> 10  
 ttttaaacca aaagcttttt gggcgaaacg ctgaaacttc gaccggtttt tcacccgcca 60  
 tccaccagtc ctaacacctc cgaccaggaa gtcatcagga atattgacca atcagaattc 120  
 gaaggatttc ctttggttaac tctgaatttt taaaaccga agtcaagagc tagtagatct 180  
 gtagacctcc gtccttcatt tctgtcattc aagctcacag ctatcatgag agacaagcga 240  
 gacacctcca acttcgacaa aagttcacca ggcagcctgt ggaactgact cccactgaca 300  
 aactctgtcg actagaatgc cctgaattct gcagatatcc atcacactgc g 351

<210> 11  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> metabolite responsive instability element

<220>  
 <223> Description of Artificial Sequence: nucleic acid  
 construct

<400> 11  
 taactctgaa tttttaaaac ccgaagtcaa gagctagta 39

C1

<210> 12  
 <211> 300  
 <212> RNA  
 <213> Human PKC Beta II

<400> 12  
 uuuuaaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60  
 uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120  
 gaaggauuuc cuuuguuaac ucugaauuuu uaaaaccga agucaagagc uaguagaucu 180  
 guagaccucc guccuucuu ucugucuuuc aagcucacag cuaucaugag agacaagcga 240  
 gacaccucca acuucgacaa aaguucacca ggcagccugu ggaacugacu cccacugaca 300

<210> 13  
 <211> 175  
 <212> RNA  
 <213> Human PKC Beta II

<400> 13  
 uuuuaaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60  
 uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120  
 gaaggauuuc cuuuguuaac ucugaauuuu uaaaaccga agucaagagc uagua 175

C1  
(end)

<210> 14  
<211> 137  
<212> RNA  
<213> Human PKC Beta II

<400> 14  
uuuuuuuaccca aaagcuuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60  
uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120  
gaaggauuuc cuuuguu 137

---